Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) announced that CEO Ronald Andrews and CMO Doug Ross will participate in the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference on September 17, 2020. The company focuses on molecular diagnostics to enhance cancer care, striving to improve patient outcomes. Recently, Oncocyte launched DetermaRx™, a test that identifies early-stage lung cancer patients at elevated risk for recurrence, and is developing DetermaIO™, a test for checkpoint immunotherapy responders.

IRVINE, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that Ronald Andrews, Chief Executive Officer, and Doug Ross, MD., Ph.D., Chief Medical Officer, will participate at the upcoming Lake Street Capital Markets 4^th Annual Best Ideas Growth Conference, being held virtually on September 17, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation

FAQ

What is the purpose of Oncocyte Corporation's participation in the conference on September 17, 2020?

Oncocyte Corporation is participating to showcase its innovative molecular diagnostics solutions at the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference.

What is DetermaRx™?

DetermaRx™ is a treatment stratification test that helps identify early-stage lung cancer patients at high risk for recurrence post-resection.

What event will Oncocyte Corporation executives attend on September 17, 2020?

Executives from Oncocyte Corporation will attend the Lake Street Capital Markets 4th Annual Best Ideas Growth Conference.

What does Oncocyte Corporation specialize in?

Oncocyte Corporation specializes in molecular diagnostics aimed at improving cancer care and patient outcomes.

What is DetermaIO™?

DetermaIO™ is a gene expression test developed by Oncocyte to identify patients who are more likely to respond to checkpoint immunotherapies.